President's panel calls for more girls, boys to get HPV vaccine

February 10, 2014
President's panel calls for more girls, boys to get HPV vaccine
It protects against cancers of the cervix, throat, rectum and penis, but too few getting the shots.

(HealthDay)—Too few American girls and boys are getting vaccinated against the cancer-causing human papillomavirus (HPV), the President's Cancer Panel reported Monday.

HPV is linked to cervical cancer as well as penis, rectal and oral cancers. One in four adults in the United States is infected with at least one type of HPV. Increasing HPV vaccination rates could prevent a large number of cancer cases and save many lives, the panel said.

"Today, there are two safe, effective, approved vaccines that prevent infection by the two most prevalent cancer-causing types, yet vaccination rates are far too low," Barbara Rimer, chair of the President's Cancer Panel, said in a panel news release.

"We are confident that if HPV vaccination for and boys is made a public health priority, hundreds of thousands will be protected from these HPV-associated diseases and cancers over their lifetimes," she added.

Currently, the U.S. Centers for Disease Control and Prevention is recommending that girls aged 11 and 12 receive either the Cervarix or Gardasil vaccines, and Gardasil is recommended for boys of similar age.

In 2012, only a third of girls aged 13 to 17 got all three recommended doses of HPV vaccine, CDC data shows. That's much lower than the federal government's goal of having 80 percent of girls aged 13 to 15 fully vaccinated against HPV by 2020, the report said.

The picture is even more disappointing for boys. Less than 7 percent of males aged 13 to 17 completed the recommended HPV vaccination series in 2012. The vaccine was recommended for boys more recently.

Boosting HPV vaccination rates to 80 percent would prevent 53,000 future cases among girls who are currently aged 12 or younger, according to the CDC.

The agency also estimates that increased vaccination would prevent thousands of cases of other HPV-associated cancers in both females and males, the report added.

A number of things need to be done to increase HPV , the panel said. These include public education and other efforts to increase teens' and parents' acceptance of the vaccines; encouraging doctors and other to recommend and give vaccinations; and making sure that the vaccines are available where teens receive health care.

Explore further: How to improve HPV vaccination rates? It starts with physicians, researchers say

More information: The U.S. National Cancer Institute has more about HPV vaccines.

Related Stories

How to improve HPV vaccination rates? It starts with physicians, researchers say

January 21, 2014
The risk of developing cervical cancer can be significantly decreased through human papillomavirus (HPV) vaccination. Despite calls from leading health and professional organizations for universal vaccination for girls ages ...

Beliefs about HPV vaccine do not lead to initiation of sex or risky sexual behavior

February 3, 2014
A new study may alleviate concerns that the human papillomavirus (HPV) vaccine leads to either the initiation of sex or unsafe sexual behaviors among teenage girls and young women.

1 in 5 boys got HPV shot in first year recommended

August 29, 2013
A new report offers a first look at how many boys are getting shots designed to protect girls from cervical cancer. Health officials say the number getting vaccinated so far is a good start.

Too few girls get HPV vaccine against cancer: CDC

August 30, 2012
(HealthDay)—Parents and doctors can do more to protect girls from cancers caused by the human papillomavirus (HPV), say U.S. health officials who are concerned by lagging HPV vaccination rates among females.

No change in HPV vaccine coverage for teen girls in 2012

July 30, 2013
(HealthDay)—In 2012 there was little increase in human papillomavirus (HPV) vaccination among teenage girls, according to a report published in the July 26 issue of the U.S. Centers for Disease Control and Prevention's ...

Lower HPV vaccination rates putting girls from ethnic minorities at risk of cancer

November 4, 2013
Girls from some ethnic minorities are less likely to be vaccinated against Human Papillomavirus (HPV), responsible for almost all cases of cervical cancer, according to new research presented at the National Cancer Research ...

Recommended for you

Soy, cruciferous vegetables associated with fewer common breast cancer treatment side effects

December 11, 2017
Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects ...

CAR T, immunotherapy bring new hope for multiple myeloma patients

December 11, 2017
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other ...

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.